Insulinorresistencia, metabolismo celular del calcio e hipertensión arterial esencial. Papel del músculo esquelético

Medicina Clinica

Volumn 107, Issue 3, 1996, Pages 102-106

  Senchez, Miguel ^a   Coca, Antonio ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ENZYME INHIBITOR; INSULIN; INSULIN RECEPTOR; PHOSPHATASE; GLUCOSE; GLUCOSE TRANSPORTER; GLYCOGEN SYNTHASE;

CALCIUM METABOLISM; CELL METABOLISM; ESSENTIAL HYPERTENSION; HUMAN; INSULIN RESISTANCE; NONHUMAN; REVIEW; SKELETAL MUSCLE; CELL; HYPERTENSION; METABOLISM; PHYSIOLOGY;

CALCIUM; CELLS; GLUCOSE; GLYCOGEN SYNTHASE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MONOSACCHARIDE TRANSPORT PROTEINS; MUSCLE, SKELETAL; PHOSPHORIC MONOESTER HYDROLASES; RECEPTOR, INSULIN;

EID: 0030585460     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Sowers JR, Zemel BM. Clinical implications of hypertension in the diabetic patient. Am J Hypertens 1990; 3: 415-424.
2. Lindner A, Kenny M, Meacham AJ. Effects of a circulating factor in patients with essential hypertension on intracellular free calcium in normal platelets. N Engl J Med 1987; 316: 509-513.
3. Resnick LM. Calcium metabolism in hypertension and allied metabolic disorders. Diabetes Care 1991; 14: 505-520.
4. Ferrannini E, Buzziogoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
5. Capaldo B, Lembo G, Napoli R, Rendina V, Albano G, Saccà L et al. Skeletal muscle is a primary site of insulin resistance in essential hypertension. Metabolism 1991; 40: 1.320-1.322.
6. Natali A, Santoro D, Palombo C, Cerri M, Ghione S, Ferrannini E. Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 1991; 17: 170-178.
7. Obermaier B, Ermel B, Biemer E, Kirsch D, Machicao F, Häring HU. Insulin receptor kinase in human skeletal muscle. FEBS Lett 1985; 186: 85-88.
8. Kahn CR, Crettaz M. Insulin receptors and the molecular mechanism of the insulin action. Diabetes Metab Rev 1985; 1: 5-32.
9. Rosen OM. After insulin binds. Science 1987; 237: 1.452-1.458.
10. Exton JH. Some thoughts on the mechanism of action of insulin. Diabetes 1991; 40: 521-526.
11. Dent P, Lavoinne A, Nakielny S, Caudwell FB, Watt P, Cohen P. The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature (Lond) 1990; 348: 302-308.
12. Cohen P. Protein phosphorylation and hormone action. Proc R Soc Lond 1988: 234: 115-144.
13. Ingebritsen TS, Cohen P. Protein phosphatases properties and role in cellular regulation. Science 1983; 221: 331-338.
14. Cohen P. Protein phosphorylation and the control of glycogen metabolism in skeletal muscle. Philos Trans R Soc Lond B Biol Sci 1983; 302: 13-25.
15. Larner J. Mediators of post-receptor action of insulin. Am J Med 1983: 17: 38-51.
16. Villar-Palasi C. Oligo and polysaccharide inhibition of muscle transferase D phosphatase. Ann NY Acad Sci 1969; 166: 719-730.
17. Sheorain VS, Juhl H, Bass M, Soderling TR. Effects of epinephrine, diabetes, and insulin on rabbit skeletal muscle glycogen synthase. Phosphorylation site occupancies. J Biol Chem 1984; 259: 7.024-7.030.
18. Bell GI. Kayano T, Buse JB, Burant CF, Takeda J, Lin D et al. Molecular biology of mammalian glucose transporters. Diabetes Care 1990; 13: 198-208.
19. Cushman SW, Wardzala LJ. Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. J Biol Chem 1980; 255: 4.758-4.762.
20. Begum N, Draznin B. Effect of streptozotocin-induced diabetes on GLUT-4 phosphorylation in rat adipocytes. J Clin Invest 1992; 90: 1.254-1.262.
21. Reusch JEB, Sussman KE, Draznin B. Inverse relationship between GLUT-4 phosphorylation and its intrinsic activity. J Biol Chem 1993; 268: 3.348-3.351.
22. Lawrence JC Jr, Hiken JF, James DE. Phosphorylation of the glucose transporter in rat adipocytes. Identification of the intracelular domain at the carboxyl terminus as a targed for phosphorylation in intact cells and in vitro. J Biol Chem 1990; 265: 2.324-2.332.
23. Taylor SI, Kadowaki T, Kadowaki H, Accili D, Cama A, McKeon C. Mutations in the insulin receptor gene in insulin resistant patients. Diabetes Care 1990; 13: 257-279.
24. Arner P, Pollare T, Lithell H, Livingston JN, Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 437-440.
25. Häring HU, Obermaier B, Ermel B et al. Insulin receptor kinase defects as a possible cause of cellular insulin resistance. Diabet Metab 1987; 13: 284-293.
26. Caro JF, Sinha MK, Raju SM, Ittoop O, Poreis WJ, Flickinger EG et al. Insulin receptor kinase in human skeletal muscle from obese subjects with and without non-insulin-dependent diabetes mellitus. J Clin Invest 1987; 82: 1.398-1.406.
27. Obermaier-Kusser B, White MF, Pongratz DE, Su Z, Ermel B, Muhlbacher C et al. A defective intramolecular autoactivation cascade may cause the reduced kinase activity of the skeletal muscle insulin from patients with non-insulin-dependent diabetes mellitus. J Biol Chem 1989; 264: 9.497-9.503.
28. Moller DE, Yokota A, Flier JS. Normal insulin receptor cDNA sequence in Pima Indians with NIDDM. Diabetes 1989; 38: 1,496-1.500.
29. O'Rahilly S, Choi WH, Patel P, Turner RC, Flier JS, Moller DE Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms. Diabetes 1991; 40: 777-782.
30. Kusari J, Verma US, Buse JB, Henry RR, Olefsky JM. Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus. J Clin Invest 1991; 88: 1.323-1.330.
31. Cocozza S, Porcellini A, Riccardi G, Monticelli A, Condorelli G, Ferrara A et al. NIDDM associated with mutation in tyrosine kinase domain of insulin receptor gene. Diabetes 1992; 41: 521-526
32. Formisano P, Riccardi G, Miele C, Condorelli G, Ferrara A, Porcellini A et al. Functional properties of an insulin receptor mutation occurring in NIDDM [resumen]. Diabetes 1992; 41 Supl: 70.
33. Häring HU. The insulin receptor: signalling mechanism and contribution to the pathogenesis of insulin resistance. Diabetologia 1991; 34: 848-861.
34. Bader S, Scholz R, Kellerer M, Tippmer S, Rett K, Mathaei S et al. Normal insulin receptor tyrosine kinase activity and glucose transporter (GLUT-4) levels in the skeletal muscle of hyperinsulinaemic hypertensive rats. Diabetologia 1992; 35: 712-718.
35. McGuire MC, Fields RM, Nyomba BL, Raz I, Bogarausc C, Tonks NK et al. Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans. Diabetes 1991; 40: 939-942.
36. Kusari J, Kenner K, Suh KI, Henri RR. Impaired tyrosine phosphatase activity in non-insulin dependent diabetes mellitus [resumen]. Diabetes 1992; 41 Supl: 184.
37. Kida Y, Esposito-Del Puente A, Bogardus C, Mott DM. Insulin resistance is associated with reduced fasting and insulin-stimulated glycogen synthase phosphatase activity in human skeletal muscle. J Clin Invest 1990; 85: 476-481.
38. Kida Y, Raz I, Maeda R, Nyomba BL, Stone K, Bogardus C et al. Defective insulin response of phosphorylase phosphatase in insulin-resistant humans. J Clin Invest 1992; 89: 610-617.
39. Freymond D, Bogardus C, Okubo M. Stone K, Mott D. Impaired insulin-stimulated muscle glycogen synthase activation in vivo in man is related to low fasting glycogen synthase phosphatase activity. J Clin Invest 1988; 82: 1.503-1.509.
40. Thompson DB, Degregorio M, Sommercorn J. Insulin resistance alters immediate early gene expression in human skeletal muscle in vivo [resumen]. Diabetes 1992; 41 Supl: 89.
41. DeFronzo RA, Bonadona RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992; 15: 318-368.
42. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321: 337-343.
43. Warram JH, Martin BH, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic patients. Ann Intern Med 1990; 113: 909-915.
44. Vaag A, Henriksen JE, Beck-Nielsen H. Decreased insulin activation of glycogen synthase in skeletal muscles in young non-obese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1992; 89: 782-788.
45. Schalin-Jäntti C, Härkönen M, Groop LC. Impaired activation of glycogen synthase in people at increased risk for developing NIDDM. Diabetes 1992; 41: 598-604.
46. Groop LC, Kankuri M, Nikula-ljas P, Koivisto V. Expression of the glycogen synthase gene in skeletal muscle of NIDDM patients and their first-degree relatives [resumen]. Diabetes 1992; 41 Supl: 68.
47. Vogt B, Mühlbacher C, Carrascose J, Obermaier-Kusser B, Seffer E, Mushack J et al. Subcellular distribution of GLUT-4 in the skeletal muscle of the lean type 2 (non-insulin-dependent) diabetic patients in the basal state. Diabetologia 1992; 35: 456-463.
48. Handberg A, Vaag A, Damsbo P, Beck-Nielsen H, Vinten J. Expression of insulin regulatable glucose transports in skeletal muscle from type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1990; 33: 625-627.
49. Pedersen O, Bak JF, Andersen PH, Lund S, Moller DE, Flier JS et al. Evidence against altered expresion of GLUT 1 or GLUT 4 in skeletal muscle of patiens with obesity or NIDDM. Diabetes 1990; 39: 865-870.
50. Friedman JE, Dohm GL, Leggett-Frazier N. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. J Clin Invest 1992; 89: 701-705.
51. Eriksson J, Koranyi L, Bourey R, Schalin-Jantti C, Widen E, Meckler M et al. Insulin resistance in type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT-4) gene in human skeletal muscle. Diabetologia 1992; 35: 143-147.
52. Edelman AM. Protein serin/threonine kinases Ann Rev Bioch 1987; 56: 567.
53. Draznin B, Lewis D, Houlder N, Sherman N, Adamo M, Garvey WT et al. Mechanism of insulin resistance induced by sustained levels of cytosolic free calcium in rat adipocytes. Endocrinology 1989; 125: 2.341-2.349.
54. Draznin B, Sussman KE, Kao M, Lewis D, Sherman NA. The existence of an optimal range of cytosolic free calcium for insulin-stimulated glucose transport in rat adipocytes. B Biol Chem 1987; 262: 14.385-14.388.
55. Reusch JE-B. Begum M, Sussman KE, Draznin B. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology 1991; 129: 3.269-3.273.
56. Draznin B, Sussman KE. Eckel RH, Kao M, Yost T, Sherman NA. Possible role of cytosolic free calcium concentrations in mediating insulin resitance of obesity and hyperinsulinemia. J Clin Invest 1988; 82: 1.848-1.852.
57. Segal S, Lloyd S, Sherman NA, Sussman KE, Draznin R. Postprandial changes in cytosolic free calcium and glucose uptake in adipocytes in obesity and non-insulin-dependent diabetes mellitus. Horm Res 1990; 34: 39-44.
58. Byyny RL, LoVerde M, Loyd S, Mitchell W, Draznin B. Cytosol calcium and insulin resistance in elderly patients with essential hypertension. Am J Hypertens 1992; 5: 459-464.
59. +-ATPase in rat aorta. Diabetes 1991; 40: 1.560-1.563.
60. Begum N, Sussman KE, Draznin B. High levels of cytosolic free calcium inhibit dephosphorylation of insulin receptor and glycogen synthase. Cell Calcium 1991; 12: 423-430.
61. 2+-induced inhibition of insulin-stimulated glucose transport. J Biol Chem 1993; 268: 3.352-3.356.
62. Begum N, Sussman KE, Draznin B. Calcium-induced inhibition of phosphoserine phosphatase in insulin target cells is mediated by the phosphorylation and activation of inhibitor 1. J Biol Chem 1992; 267: 5.959-5.963.